<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00995072</url>
  </required_header>
  <id_info>
    <org_study_id>SAIRB-09-0011</org_study_id>
    <nct_id>NCT00995072</nct_id>
  </id_info>
  <brief_title>Comparative Effects of Nebivolol and Metoprolol on Female Sexual Function</brief_title>
  <official_title>Comparative Effects of Nebivolol and Metoprolol on Female Sexual Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>East Coast Institute for Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>East Coast Institute for Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Beta-blockers (BB) are an important treatment for high blood pressure and heart disease.
      However beta-blockers can cause sexual dysfunction (SD) and this common side effect limits
      successful use of this class of medications. Sexual side effects often result in drug
      discontinuation, compromising therapy goals. The investigators are conducting the study to
      determine if nebivolol, a newer beta blocker that is selective for receptors in the heart and
      causes vasodilation in the body causes fewer sexual side effects, or even improves sexual
      function, compared with metoprolol succinate.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This protocol is designed to compare the effects two beta blockers, nebivolol (Bystolic) 5-10
      mg daily with metoprolol succinate (Toprol XL) 100-200 mg daily on sexual function in
      post-menopausal women with high blood pressure. The study is composed of 2 treatment phases.
      At baseline subjects are randomized to either nebivolol 5 mg once daily or metoprolol
      succinate 100 mg once daily. After randomization, subjects are treated for 12 weeks with
      double blind therapy. Following double-blind therapy subjects enter a 2-week washout phase
      and are subsequently switched to the alternate therapy.

      After 4 weeks (visits 3 and 7) of double-blind treatment with either nebivolol 5 mg once
      daily or metoprolol succinate 100 mg once daily subjects will be evaluated and the need for
      dosage titration assessed. If blood pressure is not at goal the dosage of study medication
      will be doubled to nebivolol 10 mg once daily or metoprolol succinate 200 mg once daily. If
      blood pressure remains uncontrolled after 8 weeks of double blind treatment with study
      medication open label amlodipine 5 mg will be initiated (visits 4 and 8) at the discretion of
      the principal investigator. During double blind treatment subjects will be evaluated in
      clinic every 4 weeks.

      The primary efficacy variable is the change from baseline in Changes in Sexual Functioning
      Questionnaire (CSFQ) and the Female Sexual Function Index (FSFI).

      The primary study objective is to determine whether nebivolol causes fewer sexual side
      effects compared with metoprolol succinate and if nebivolol improves FSF in women. FSF will
      be assessed with the above questionnaires-FSFI and CSFQ.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Female Sexual Function Index</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>This scale is a self-reported instrument used to detect female sexual function. The scale ranges from 2 to 36. The higher score indicates higher sexual function.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Sexual Functioning Questionnaire Score</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>This scale is a self-reported instrument used to detect sexual functioning. The scale ranges from 14 to 70. The higher scores reflects higher sexual functioning.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Hypertension</condition>
  <condition>Female Sexual Dysfunction</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nebivolol 5 mg daily for 12 weeks followed by Metoprolol succinate 100 mg daily for 12 weeks. A two week washout (no medication) is completed prior to switching to metoprolol.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Metoprolol succinate 100 mg daily for 12 weeks followed by nebivolol 5 mg daily for 12 weeks. A two week washout (no medication) is completed prior to switching to nebivolol.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nebivolol and metoprolol succinate</intervention_name>
    <description>Subjects randomized to treatment Arm A will receive nebivolol 5 mg once daily for 12 weeks. After 12 weeks, double blind therapy will be discontinued and patients will undergo a wash-out period of study therapy over 2 weeks. Subjects randomized to treatment Arm A will then receive metoprolol succinate 100 mg once daily. Subjects will continue double blind therapy for a total duration of 12 weeks.</description>
    <arm_group_label>Arm A</arm_group_label>
    <other_name>nebivolol</other_name>
    <other_name>Bystolic</other_name>
    <other_name>metoprolol succinate</other_name>
    <other_name>Toprol XL</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>metoprolol succinate and nebivolol</intervention_name>
    <description>Subjects randomized to treatment Arm B will receive metoprolol succinate 100mg once daily for 12 weeks. After 12 weeks, double blind therapy will be discontinued and patients will undergo a wash-out period of study therapy over 2 weeks. Subjects randomized to treatment Arm B will then receive nebivolol 5 mg once daily. Subjects will continue double blind therapy for a total duration of 12 weeks.</description>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>nebivolol</other_name>
    <other_name>Bystolic</other_name>
    <other_name>metoprolol succinate</other_name>
    <other_name>Toprol XL</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Over the age of 40 years

          2. Postmenopausal (according to self report of 12 consecutive months of amenorrhea, serum
             FSH concentrations greater than 40 international units/L, or surgical history
             consistent with menopause)

          3. In a stable monogamous relationship with a male partner for at least 6 months

          4. History of hypertension, treated or untreated

          5. Requirement for the initiation of an anti-hypertensive agent OR addition of another
             anti-hypertensive medication (according to the principal investigator and based on
             clinical judgment) OR patients requiring monotherapy with an anti-hypertensive that
             wish to participate in the study and are willing to undergo a two week wash-out of
             current anti-hypertensive therapy

          6. Provide written informed consent prior to participation.

        Exclusion Criteria:

          1. Properly measured clinic SBP &gt; 170 mmHg

          2. Advanced AV block

          3. Severe hepatic disease

          4. Heart rate &lt; 55 beats/min (and not currently on beta blocker therapy)

          5. Pregnancy or lactation

          6. Heart failure with ejection fraction less than 0.40

          7. History of myocardial infarction

          8. History of Raynaud's syndrome

          9. Patients with alcoholism or recreational drug use will be excluded due to concerns
             about the ability to comply with the study requirements.

         10. Major psychiatric disorder not well controlled with treatment

         11. Spinal cord injury

         12. Severe respiratory disease, which in the opinion of the investigator contraindicates
             BB treatment

         13. Poorly controlled diabetes mellitus (â‰¥ 9%)

         14. Persistent arrhythmia
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Benjamin Epstein, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>East Coast Institute for Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Family Practice</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.eastcoastresearch.net</url>
    <description>Related Info</description>
  </link>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>October 12, 2009</study_first_submitted>
  <study_first_submitted_qc>October 13, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 14, 2009</study_first_posted>
  <results_first_submitted>April 7, 2018</results_first_submitted>
  <results_first_submitted_qc>March 15, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">March 29, 2019</results_first_posted>
  <last_update_submitted>March 15, 2019</last_update_submitted>
  <last_update_submitted_qc>March 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>East Coast Institute for Research</investigator_affiliation>
    <investigator_full_name>Benjamin Epstein</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>sexual dysfunction</keyword>
  <keyword>female</keyword>
  <keyword>hypertension</keyword>
  <keyword>high blood pressure</keyword>
  <keyword>beta blockers</keyword>
  <keyword>metoprolol</keyword>
  <keyword>nebivolol</keyword>
  <keyword>Bystolic</keyword>
  <keyword>Toprol XL</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metoprolol</mesh_term>
    <mesh_term>Nebivolol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>4 subjects were randomized and dropped from the study prior to taking the study medication</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Nebivolol 5 mg Daily First, Then Metoprolol Succinate 100 mg</title>
          <description>Nebivolol 5 mg daily for 12 weeks followed by Metoprolol succinate 100 mg daily for 12 weeks. A two week washout (no medication) is completed prior to switching to metoprolol.
nebivolol and metoprolol succinate: Subjects randomized to treatment Arm A will receive nebivolol 5 mg once daily for 12 weeks. After 12 weeks, double blind therapy will be discontinued and patients will undergo a wash-out period of study therapy over 2 weeks. Subjects randomized to treatment Arm A will then receive metoprolol succinate 100 mg once daily. Subjects will continue double blind therapy for a total duration of 12 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Metoprolol Succinate 100 mg First, Then Nebivolol 5 mg Daily</title>
          <description>Metoprolol succinate 100 mg daily for 12 weeks followed by nebivolol 5 mg daily for 12 weeks. A two week washout (no medication) is completed prior to switching to nebivolol.
metoprolol succinate and nebivolol: Subjects randomized to treatment Arm B will receive metoprolol succinate 100mg once daily for 12 weeks. After 12 weeks, double blind therapy will be discontinued and patients will undergo a wash-out period of study therapy over 2 weeks. Subjects randomized to treatment Arm B will then receive nebivolol 5 mg once daily. Subjects will continue double blind therapy for a total duration of 12 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Nebivolol 5 mg Daily First, Then Metoprolol Succinate 100 mg</title>
          <description>Nebivolol 5 mg daily for 12 weeks followed by Metoprolol succinate 100 mg daily for 12 weeks. A two week washout (no medication) is completed prior to switching to metoprolol.
nebivolol and metoprolol succinate: Subjects randomized to treatment Arm A will receive nebivolol 5 mg once daily for 12 weeks. After 12 weeks, double blind therapy will be discontinued and patients will undergo a wash-out period of study therapy over 2 weeks. Subjects randomized to treatment Arm A will then receive metoprolol succinate 100 mg once daily. Subjects will continue double blind therapy for a total duration of 12 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Metoprolol Succinate 100 mg First, Then Nebivolol 5 mg Daily</title>
          <description>Metoprolol succinate 100 mg daily for 12 weeks followed by nebivolol 5 mg daily for 12 weeks. A two week washout (no medication) is completed prior to switching to nebivolol.
metoprolol succinate and nebivolol: Subjects randomized to treatment Arm B will receive metoprolol succinate 100mg once daily for 12 weeks. After 12 weeks, double blind therapy will be discontinued and patients will undergo a wash-out period of study therapy over 2 weeks. Subjects randomized to treatment Arm B will then receive nebivolol 5 mg once daily. Subjects will continue double blind therapy for a total duration of 12 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="21"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>The number analysed in rows differs from overall due to dropouts.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="9"/>
                    <count group_id="B2" value="12"/>
                    <count group_id="B3" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="9"/>
                    <count group_id="B2" value="12"/>
                    <count group_id="B3" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="9"/>
                    <count group_id="B2" value="12"/>
                    <count group_id="B3" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Female Sexual Function Index</title>
        <description>This scale is a self-reported instrument used to detect female sexual function. The scale ranges from 2 to 36. The higher score indicates higher sexual function.</description>
        <time_frame>Baseline, 12 weeks</time_frame>
        <population>The number of participants analyzed for the measure are participants that had data available for both of the study periods.</population>
        <group_list>
          <group group_id="O1">
            <title>Nebivolol 5 mg Daily</title>
            <description>Nebivolol 5 mg daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Metoprolol Succinate 100 mg Daily</title>
            <description>Metoprolol succinate 100 mg daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Female Sexual Function Index</title>
          <description>This scale is a self-reported instrument used to detect female sexual function. The scale ranges from 2 to 36. The higher score indicates higher sexual function.</description>
          <population>The number of participants analyzed for the measure are participants that had data available for both of the study periods.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.24" spread="9.183"/>
                    <measurement group_id="O2" value="1.42" spread="5.262"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Sexual Functioning Questionnaire Score</title>
        <description>This scale is a self-reported instrument used to detect sexual functioning. The scale ranges from 14 to 70. The higher scores reflects higher sexual functioning.</description>
        <time_frame>Baseline, 12 weeks</time_frame>
        <population>The number of participants analyzed for the measure are participants that had data available for both of the study periods.</population>
        <group_list>
          <group group_id="O1">
            <title>Nebivolol 5 mg Daily</title>
            <description>Nebivolol 5 mg daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Metoprolol Succinate 100 mg Daily</title>
            <description>Metoprolol succinate 100 mg daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Sexual Functioning Questionnaire Score</title>
          <description>This scale is a self-reported instrument used to detect sexual functioning. The scale ranges from 14 to 70. The higher scores reflects higher sexual functioning.</description>
          <population>The number of participants analyzed for the measure are participants that had data available for both of the study periods.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.38" spread="7.600"/>
                    <measurement group_id="O2" value="0.85" spread="8.315"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Adverse Events were collected but the data were destroyed and are not available for reporting.</desc>
      <group_list>
        <group group_id="E1">
          <title>Nebivolol 5 mg</title>
          <description>Nebivolol 5 mg daily</description>
        </group>
        <group group_id="E2">
          <title>Metoprolol Succinate 100 mg</title>
          <description>Metoprolol succinate 100 mg daily</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The study had a lower than anticipated enrollment and a high drop-out rate due to loss of follow-upâ€”although the drop-out rate was not unexpected based on the study population.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Benjamin Epstein, PharmD</name_or_title>
      <organization>ECIR</organization>
      <phone>904-854-1354</phone>
      <email>benjamin.epstein@eastcoastresearch.net</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

